Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pharma Firms Form Antibody Alliances

by Ann M. Thayer
November 16, 2009 | A version of this story appeared in Volume 87, Issue 46

Bristol-Myers Squibb and Alder Biopharmaceuticals will jointly develop and commercialize the monoclonal antibody ALD518, which has completed early Phase II clinical trials as a rheumatoid arthritis treatment. BMS will pay $85 million upfront and up to $964 million in potential milestone payments in return for the right to develop ALD518 for all indications except cancer. Alder can also require that BMS invest up to $20 million in a future initial stock offering. Separately, Sanofi-Aventis and Regeneron Pharmaceuticals have extended their monoclonal antibody alliance by five years, through 2017. Starting next year, Sanofi will increase its annual funding commitment by 60% to $160 million. The partners hope to advance four to five therapeutic antibodies into development each year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.